Celsion Announces First Patient Randomized in the Gene-Mediated Immunotherapy (GEN-1) Study of Newly Diagnosed Stage III/IV Ovarian Cancer Patients
September 06, 2018 08:00 ET | Celsion CORP
OVATION II Study Will Evaluate Initial and Maintenance Dosing of GEN-1 on Progression-Free Survival in a Two-Arm, Randomized Trial of Up to 130 Patients LAWRENCEVILLE, N.J., Sept. 06, 2018 (GLOBE...